Related Experiment Video
Updated: Jul 17, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
Published on: September 30, 2021
Indications for use of recombinant factor VIIa: a case study with implications for research
1New Hanover Regional Medical Center, Wilmington, NC 28402, USA. marylou.moeller@nhhn.org
Abstract:
The purpose of this case study was to explore the current use of recombinant factor VIIa to control hemorrhage in the trauma patient. Despite aggressive blood product replacement and surgical intervention, uncontrolled bleeding and resultant coagulopathy are lethal to the trauma patient. What is the correlation between this drug and the hemorrhagic trauma patient? Quite simply--does it work? Curiosity may have killed the cat, but this case study clearly demonstrates the need for further research and satisfactory answers to questions illuminated by this case.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Inhibitors of Viral Protein Synthesis
